pncA Gene Mutations Associated with Pyrazinamide Resistance in Drug-Resistant Tuberculosis, South Africa and Georgia - Volume 23, Number 3—March 2017 - Emerging Infectious Disease journal - CDC

pncA Gene Mutations Associated with Pyrazinamide Resistance in Drug-Resistant Tuberculosis, South Africa and Georgia

Technical Appendix

Salim Allana, Elena Shashkina, Barun Mathema, Nino Bablishvili, Nestani Tukvadze, N. Sarita Shah, Russell R. Kempker, Henry M. Blumberg, Pravi Moodley, Koleka Mlisana, James C.M. Brust, and Neel R. Gandhi

Author affiliations: Emory University Rollins School of Public Health and School of Medicine, Atlanta, Georgia, USA (S. Allana, R.R. Kempker, H.M. Blumberg, N.R. Gandhi); Rutgers University—Public Health Research Institute, Newark, New Jersey, USA (E. Shashkina); Columbia University Mailman School of Public Health, New York, New York, USA (B. Mathema); National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia (N. Bablishvili, N. Tukvadze); Centers for Disease Control and Prevention, Atlanta (N.S. Shah); University of KwaZulu-Natal and National Health Laboratory Service, Durban, South Africa (P. Moodley, K. Mlisana); Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA (J.C.M. Brust)

Cite This Article

Abstract

Although pyrazinamide is commonly used for tuberculosis treatment, drug-susceptibility testing is not routinely available. We found polymorphisms in the pncA gene for 70% of multidrug-resistant and 96% of extensively drug-resistant Mycobacterium tuberculosis isolates from South Africa and Georgia. Assessment of pyrazinamide susceptibility may be prudent before using it in regimens for drug-resistant tuberculosis.

Drug-resistant tuberculosis (TB) poses a significant threat to global health, with an estimated 480,000 new cases of multidrug-resistant tuberculosis (MDR TB) in 2014; 10% of these cases were classified as extensively drug-resistant tuberculosis (XDR TB) (1). MDR and XDR TB are associated with high mortality rates because of limited treatment options (2,3). Drug-susceptibility testing (DST) is critical for constructing MDR and XDR TB treatment regimens.

Pyrazinamide is a critical component of first-line TB regimens but is also recommended for use in drug-resistant TB regimens (4). Despite widespread use, phenotypic DST for pyrazinamide is not routinely performed because of the precise acidic conditions required (5). However, acidic environments also inhibit the growth of Mycobacterium tuberculosis, making phenotypic pyrazinamide DST challenging even in sophisticated TB laboratories. The need for pyrazinamide DST is underscored by the potential synergy between pyrazinamide and new TB drugs under study for treatment of drug-susceptible and drug-resistant TB (6).

The development of rapid molecular tests has simplified testing for drug resistance. Assays detect resistance-conferring mutations in genes associated with phenotypic resistance to isoniazid, rifampin, fluoroquinolones, ethambutol, aminoglycosides, and capreomycin. Genotypic testing for pyrazinamide may provide a simpler method for assessing drug susceptibility (7). Pyrazinamide resistance arises through genetic mutations in the pncA gene (8). pncA encodes pyrazinamidase, which converts pyrazinamide into pyrazinoic acid for its antimycobacterial activity. However, data on the frequency and diversity of pncA mutations in clinical settings are limited.

We characterized the frequency and diversity of polymorphisms in the pncA gene and estimated the prevalence of pyrazinamide resistance among patients with MDR and XDR TB in South Africa and the country of Georgia. Ethics approval for the study was obtained from Emory University, Albert Einstein College of Medicine, National Center for Tuberculosis and Lung Diseases, University of KwaZulu-Natal, and the Centers for Disease Control and Prevention.

The Study

We performed a cross-sectional study examining pncA polymorphisms in M. tuberculosis isolates from a convenience sample of patients with MDR or XDR TB who were prospectively enrolled in studies from KwaZulu-Natal, South Africa (n = 451, diagnosed 2011–2014), and Georgia (n = 103, diagnosed November 2011–April 2012) (Technical Appendix[PDF - 218 KB - 3 pages]). Cultures and DST were performed at the provincial TB reference laboratory in Durban, South Africa, and the National Reference Laboratory in Tbilisi, Georgia. Samples underwent PCR amplification followed by standard capillary sequencing of the pncA promoter and coding DNA sequence at the Public Health Research Institute in Newark, New Jersey, USA, as previously described (9). Polymorphisms were identified by alignment of nucleotide sequences to the H37Rv reference strain by using ClustalW2 (http://www.ebi.ac.uk/Tools/msa/clustalw2/). We calculated the frequency of each pncA polymorphism and classified mutations as synonymous or nonsynonymous. We compared polymorphisms with those reported in the literature to identify any that are known to be associated with phenotypic susceptibility and to determine the proportion that are likely to confer phenotypic resistance (10–15).

To determine the effect of clonal expansion of MDR and XDR TB on the diversity of pncA mutations, we also compared IS6110-based restriction fragment-length polymorphism (RFLP) patterns with pncA mutations for the isolates from South Africa (conducted at the Public Health Research Institute). The distribution of RFLP patterns among isolates with identical pncA mutations was examined to determine if the pncA mutation arose de novo or may have been transmitted.

We completed targeted pncA gene sequencing for 554 unique patient-isolates [1 isolate/patient], 167 MDR TB and 387 XDR TB; of these, 99 (59%) of MDR TB and 215 (56%) of XDR TB patients had previously received treatment for TB. A pncA polymorphism was found in 117 (70%) MDR TB and 370 (96%) XDR TB isolates (Tables 1, 2). The proportion of MDR TB and XDR TB isolates with pncA polymorphisms did not differ significantly between those from South Africa and Georgia (MDR, 68% vs. 72%, p = 0.74; XDR, 96% vs. 90%, p = 0.73, respectively).

A total of 69 distinct pncA polymorphisms were identified (Tables 1 and 2). Of these, 12 were insertions (313 patient-isolates), 5 were deletions (6 patient-isolates), and 52 were single-nucleotide polymorphisms (SNPs; 168 patient-isolates); all but 2 of these were nonsynonymous. No polymorphism was found in common between the isolates from South Africa and Georgia. Among the pncA SNPs identified, only 6 (9 patient-isolates) have previously been associated with phenotypic pyrazinamide susceptibility (10–12); 40 SNPs have been associated with phenotypic pyrazinamide resistance (146 patient-isolates), and 7 SNPs were not previously reported (23 patient-isolates) (10–15).

There were 34 polymorphisms identified from South Africa, of which 14 (41%, constituting 388 patient-isolates) were present in >1 patient (Table 1). We found that, for 382 (98%) of 388 patients, the RFLP pattern was identical to that of at least 1 other patient with the same pncA mutation (Table 1). Moreover, each pncA polymorphism was associated with only 1 RFLP pattern in 10 of the 14 polymorphisms. By comparison, 13 RFLP patterns were seen among the 40 patients with a wild-type pncA sequence.

Conclusions

In this study, we found that 70% of MDR TB and 96% XDR TB patient-isolates had pncA polymorphisms. Given the high likelihood of frameshift mutations resulting in resistance and the high specificity (94%–98%) of pncA SNPs for pyrazinamide resistance (13,14), we estimate that at least 56%–66% of MDR TB and 90%–95% of XDR TB cases from these settings are likely to be resistant to pyrazinamide. Only a small number of mutations were synonymous, previously associated with pyrazinamide susceptibility, or had an SNP for which phenotypic susceptibility has not been previously tested. This finding has implications regarding the effectiveness of empiric use of pyrazinamide for drug-resistant TB or novel treatment regimens. Further studies are needed to fully determine the association of pncA mutations with treatment outcomes.

A diversity of pncA mutations—69 distinct polymorphisms—were observed among MDR and XDR TB patients, of which none were shared in common between the isolates from South Africa and Georgia. Most pncA polymorphisms were unique to individual patients. When the same pncA polymorphism was seen in >1 patient, the IS6110 RFLP pattern was nearly always similar, suggesting that the pncA mutation was acquired before transmission. The diversity of polymorphisms underscores previous findings that there is no clear hotspot for pncA mutations (12), unlike resistance-conferring regions for other TB drugs (e.g., rpoB, katG) (11). Development of rapid molecular tests for pyrazinamide susceptibility may be hampered by the lack of a hotspot for mutations; 1 assay has been developed to detect the full wildtype pncA sequence, but its diagnostic accuracy has not yet been adequately tested (7).

A limitation of our study is that phenotypic pyrazinamide susceptibility testing was not performed on the sequenced isolates. Nonetheless, correlation with phenotypic testing has been previously reported in the literature for most polymorphisms, enabling us to estimate the proportion likely to be pyrazinamide resistant (10–15). In addition, the studies that provided these isolates were not specifically designed to be representative of all diagnosed cases of drug-resistant TB; nonetheless, the study populations were carefully selected to provide a high level of generalizability to the broader population. National drug resistance surveys that include pyrazinamide genotypic and phenotypic susceptibility should be designed to confirm these findings.

The high prevalence of pncA polymorphisms from geographically disparate countries suggests that guidelines to empirically use pyrazinamide in drug-resistant TB regimens, including shorter MDR TB regimens (4), should be reconsidered. Simplified assays to test pyrazinamide susceptibility are needed, although they may be difficult to develop given the genotypic or phenotypic complexities. Considering the potential synergy of pyrazinamide with new TB drugs, routine assessment of pyrazinamide will be increasingly necessary and useful.

Dr. Allana is assistant director of the Emory TB/HIV Research Group at the Emory Rollins School of Public Health in Atlanta. His primary research interest is the intersection of the drug-resistant TB and HIV epidemics in South Africa.

Acknowledgment

This study was funded by grants from the US National Institutes of Health: R01AI089349 (N.R.G.), R01AI087465 (N.R.G.), K23AI103044 (R.R.K.), and D43TW007124 (H.M.B.). The study also received support in part from the following National Institutes of Health grants: K23AI083088 (J.C.M.B.), K24AI114444 (N.R.G.), Emory Center for AIDS Research P30AI050409, Einstein/Montefiore Institute for Clinical and Translational Research UL1 TR001073, and Atlanta Clinical and Translational Science Institute UL1TR000454.

References

World Health Organization. Global tuberculosis report 2015. Geneva: The Organization; 2015. Report no. WHO/HTM/TB/2015.22.
Shah NS, Pratt R, Armstrong L, Robison V, Castro KG, Cegielski JP. Extensively drug-resistant tuberculosis in the United States, 1993-2007. JAMA. 2008;300:2153–60. DOI PubMed
Gandhi NR, Shah NS, Andrews JR, Vella V, Moll AP, Scott M, et al.; Tugela Ferry Care and Research (TF CARES) Collaboration. HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med. 2010;181:80–6. DOI PubMed
World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis. Geneva: The Organization; 2016. Report no. WHO/HTM/TB/2016.04.
Zhang Y, Permar S, Sun Z. Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J Med Microbiol. 2002;51:42–9. DOI PubMed
RESIST-TB. DR-TB clinical trials progress report. 2016 [cited 2016 May 17]. http://www.resisttb.org/?page_id=1602
Sekiguchi J, Nakamura T, Miyoshi-Akiyama T, Kirikae F, Kobayashi I, Augustynowicz-Kopec E, et al. Development and evaluation of a line probe assay for rapid identification of pncA mutations in pyrazinamide-resistant mycobacterium tuberculosis strains. J Clin Microbiol. 2007;45:2802–7. DOI PubMed
Scorpio A, Zhang Y. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat Med. 1996;2:662–7. DOI PubMed
Sreevatsan S, Pan X, Stockbauer KE, Connell ND, Kreiswirth BN, Whittam TS, et al. Restricted structural gene polymorphism in the Mycobacterium tuberculosis complex indicates evolutionarily recent global dissemination. Proc Natl Acad Sci U S A. 1997;94:9869–74. DOI PubMed
Whitfield MG, Warren RM, Streicher EM, Sampson SL, Sirgel FA, van Helden PD, et al. Mycobacterium tuberculosis pncA polymorphisms that do not confer pyrazinamide resistance at a breakpoint concentration of 100 micrograms per milliliter in MGIT. J Clin Microbiol. 2015;53:3633–5. DOI PubMed
Sandgren A, Strong M, Muthukrishnan P, Weiner BK, Church GM, Murray MB. Tuberculosis drug resistance mutation database. PLoS Med. 2009;6:e2. DOI PubMed
Miotto P, Cabibbe AM, Feuerriegel S, Casali N, Drobniewski F, Rodionova Y, et al. Mycobacterium tuberculosis pyrazinamide resistance determinants: a multicenter study. MBio. 2014;5:e01819–14. DOI PubMed
Akhmetova A, Kozhamkulov U, Bismilda V, Chingissova L, Abildaev T, Dymova M, et al. Mutations in the pncA and rpsA genes among 77 Mycobacterium tuberculosis isolates in Kazakhstan. Int J Tuberc Lung Dis. 2015;19:179–84. DOI PubMed
Xia Q, Zhao LL, Li F, Fan YM, Chen YY, Wu BB, et al. Phenotypic and genotypic characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates in Zhejiang, China. Antimicrob Agents Chemother. 2015;59:1690–5. DOI PubMed
Ramirez-Busby SM, Valafar F. Systematic review of mutations in pyrazinamidase associated with pyrazinamide resistance in Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother. 2015;59:5267–77. DOI PubMed